Finanzen von Xenon Pharmaceuticals Inc (XENE)XENEXenon Pharmaceuticals Inc

Evaluating the bottom line, Xenon Pharmaceuticals Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -43.62%, provide a clear picture of how effectively XENE converts its operational activities into shareholder value.

In the context of the broader market, XENE competes directly with industry leaders such as PTCT and GRFS. With a market capitalization of $6.18B, it holds a leading position in the sector. When comparing efficiency, XENE's gross margin of N/A stands against PTCT's 91.19% and GRFS's 37.57%. Such benchmarking helps identify whether Xenon Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% in Q1 2025, but has consistently reported net income losses, with the latest being -$110.736 million in Q2 2026.